Netherlands Pharmaceuticals & Healthcare Report Q2 2014 - New Study Released
We anticipate further restrictions to medicine prices in 2014 under the Medicines Prices Act, which will subdue the outlook for both patented and generic drugmakers in the country. This comes despite expectations for a return to positive economic growth in 2014, as the Dutch government will persist with austerity measures to comply with EU budgetary requirements. While our short-term outlook for healthcare expenditure is steady, spending growth has levelled off since 2011, with the proportion of GDP allocated to healthcare...
View full press release